Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Minister Komiyama Calls on Opposition to Join Efforts to Consider Third-Party Organization
December 9, 2011
- US FDA Begins Review of Risks of Serious Bleeding in Patients Taking Dabigatran
December 9, 2011
- NHI Drug Pricing Subcommittee to Apply 80% Rule for Combination Drugs to Injectables, Topical Drugs
December 8, 2011
- Gov’t Tax Commission Decides to Extend Temporary R&D Tax Credits
December 8, 2011
- CSIMC Submits Opinion on Medical Fee Revision Including Views of Both Healthcare Providers and Medical Bill Payers
December 8, 2011
- MHLW Proposes Penalty for Companies that Receive Premium but Refuse Development Requests
December 8, 2011
- Payers, Care Providers Agree at CSIMC on Need for Price Cuts for Long-listed Drugs
December 8, 2011
- Representatives of Payers, Care Providers Argue Against Freeze on Prices of Essential Drugs
December 8, 2011
- 2010 Survey Shows OB/GYN Doctors, Surgeons Rise in Number
December 7, 2011
- MHLW Reform Plan Calls for “Reductions in NHI Prices of Original Drugs”
December 6, 2011
- Orphan Drug Designation Approved for Everolimus, Tafamidis Meglumine
December 6, 2011
- Premium for New Drug Development to Be Continued on Trial Basis: CSIMC Expert Subcommittee
December 6, 2011
- 2010 Survey Shows Rise in Numbers of OB/GYN Doctors, Surgeons
December 6, 2011
- Takeda’s Novel ARB Azilva Recommended for Approval: PAFSC First Committee
December 5, 2011
- CSIMC General Assembly Points Out Some “Reckless” Evaluations on Policy Screening Report
December 5, 2011
- 80% Rule for Combination Drugs Will Be Applied to Injectables, Topical Drugs: MHLW Proposal
December 5, 2011
- MHLW Announces Results of Reexamination for Iressa, Remicade as Category I
December 5, 2011
- PAFSC 2nd Committee Recommends Designation of Thalidomide, Imatinib Mesylate as Orphan Drugs
December 5, 2011
- Decision on Price Freeze for Medically Essential Drugs to Be Postponed
December 5, 2011
- Expert Subcommittee Approves 60% Pricing Rule for Some New Generics Only
December 5, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…